IBJNews

Lilly’s Bydureon wins backing of European drug panel

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. and Amylin Pharmaceuticals Inc., rebuffed twice in their bid for U.S. approval of a weekly diabetes drug, won the backing of European Union regulators for the product.

Bydureon should be approved by the European Commission for Type 2 diabetes in adults, the London-based European Medicines Agency said Friday in a statement, following a 183-day review by its Committee for Medicinal Products for Human Use.

The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.

Bydureon is a longer-acting version of the twice-daily diabetes injection Byetta sold by San Diego-based Amylin and Indianapolis-based Lilly. A weekly drug would be more convenient for patients and help the company compete with Novo Nordisk A/S, the world’s biggest insulin maker.

Amylin lost 46 percent of its market value Oct. 20 after saying the U.S. Food and Drug Administration wanted a study assessing the drug’s heart risks. The shares rose $2.24, or 20 percent, to $13.50 each overnight in premarket trading.

Byetta, a synthetic version of a substance found in the saliva of the Gila monster, stimulates pancreas cells to produce the hormone insulin when blood sugar is high. Novo Nordisk’s Victoza, which works in a similar way, can be taken once a day instead of twice. Victoza had worldwide sales of $450 million last year, Novo Nordisk said Feb. 2.

Lilly markets Byetta outside the U.S. and co-markets it with Amylin in the U.S. The drug was developed by Amylin, and the technology enabling it to be used in a longer-acting form was developed by Waltham, Mass.-based Alkermes Inc. Alkermes will receive royalties of about 8 percent on Bydureon sales.

Amylin and its marketing partners plan to submit a response to the FDA in the second half of 2011, the companies said in a March 3 statement. Shares in Amylin and Alkermes plunged that same day after a study showed Bydureon didn’t control the disease better than Victoza.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing

ADVERTISEMENT